Glycerol dehydratase variant and use thereof
The fused glycerol dehydratase variant addresses inactivation issues by linking alpha and beta-subunits with specific substitutions, achieving enhanced stability and activity, and reducing coenzyme B12 requirements for efficient production of 3-hydroxypropionic acid and 1,3-propanediol.
Patent Information
- Application Number
- PCT/KR2024/007479
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-29
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Glycerol dehydratase enzymes are prone to inactivation due to binding of glycerol or oxygen, leading to reduced activity and efficiency in converting glycerol to 3-hydroxypropionic acid or 1,3-propanediol, especially under low coenzyme B12 concentrations.
A fused glycerol dehydratase variant is developed by linking the alpha-subunit and beta-subunit with specific amino acid substitutions, enhancing resistance to inactivation by glycerol and oxygen, and maintaining high activity even at low coenzyme B12 concentrations.
The fused variant exhibits improved stability and activity, increasing resistance to oxygen inactivation by 37% and enhancing glycerol conversion efficiency by approximately 5-fold, while reducing the need for expensive coenzyme B12, thus improving the production of 3-hydroxypropionic acid and 1,3-propanediol.
Smart Images

Figure KR2024007479_05122024_PF_FP_ABST
Abstract
Description
Glycerol dehydratase variants and uses thereof
[0001] The present invention relates to a glycerol dehydratase variant and its use, and more particularly, to a fused glycerol dehydratase variant that exhibits excellent activity even under conditions of low concentrations of coenzyme B12 by improving inactivation of coenzyme B12 by oxygen or improving activity toward glycerol as a substrate, and its use.
[0002]
[0003] Glycerol dehydratase has the advantage of utilizing glycerol, a byproduct of biodiesel production. Glycerol is converted to 3-hydroxypropionaldehyde (3-HPA) by glycerol dehydratase, which then undergoes aldehyde dehydrogenase to produce 3-hydroxypropionic acid (3-HP) or 1,3-propanediol oxidoreductase to produce 1,3-PDO (Figure 1). Due to the simplicity of this pathway, many researchers have studied the production of 3-HP and 1,3-PDO through this pathway in various microorganisms (Drozdzynska, A., et al., BioTechnologia, 92(1), 92-100. (2011); Valdehuesa, et al., Applied microbiology and biotechnology, 97, 3309-3321. (2013); Mitrea, L., et al., Microbial Cell Factories, 16, 1-17. (2017)).
[0004] Coenzyme B12-dependent glycerol dehydratase has been widely used in the reaction despite its requirement for expensive vitamin B12. The cobalamin derivative used as a coenzyme in the coenzyme B12-dependent glycerol dehydratase reaction is a complex organic cofactor found in nature. The active form of cobalamin (adenosylcobalamin, AdoCbl) of coenzyme B12-dependent glycerol dehydratase is located in a pocket formed at the interface of the α and β subunits. Cobalamin is composed of a cyclic tetrapyrrole structure (corrin ring) with a cobalt atom at the center. The corrin ring has four propionamide, three acetamide, and eight methyl groups, as well as a nucleotide tail containing dimethylbenzamidazole (DBI) (Figure 2). These peripheral groups are well positioned at the α, β subunit interface for radical reaction-based catalysis and interact with residues at the interface of the enzyme (Toraya, T., et al., Biochemistry 18(3), 417-426. (1979); Toraya, T., & Abeles, RH Archives of Biochemistry and Biophysics, 203(1), 174-180. (1980)). The coenzyme B12-dependent glycerol dehydratase shown in the above Figure 2 converts glycerol to 3-hydroxypropionaldehyde according to the following mechanism: (1) The binding of the substrate glycerol to glycerol dehydratase induces a conformational change in the enzyme, which increases the bond length between the cobalt atom of coenzyme B12 and the adenosyl (red) moiety from 1.95 - 2.2 Å to 2.5 Å, thereby breaking the carbon-cobalt bond. (2) The adenosyl radical thus generated rotates along the glycosidic bond of the substrate, abstracting a hydrogen atom from the substrate to form a substrate radical. (3) Then, the OH group of the second carbon moves to the terminal carbon, and a new radical is generated at the second carbon.(4) The generated 1,1-diol is unstable and easily converted to an aldehyde group by releasing water. (5) The hydrogen atom is then abstracted back to 5'deoxyadenosine, ultimately generating an aldehyde product and an adenosyl radical (Mancia, et al., Structure, 4(3), 339-350. (1996); Shibata, N., et al., Structure, 7(8), 997-1008. (1999); Kamachi, T., et al., Chemistry-A European Journal, 13(28), 7864-7873. (2007)).
[0005] However, the above glycerol dehydratase has a problem in that it is inactivated by the binding of coenzyme B12, which has been deactivated by the substrate glycerol or oxygen, to the active site of the enzyme. In one aspect, glycerol acts as both a substrate and an inhibitor of glycerol dehydratase. Nevertheless, glycerol dehydratase can convert substrates without inhibition for a short period of time. The cause of the inactivation is thought to be the chirality of the substrate. Although glycerol is not a chiral molecule, it is classified as a pro-chiral molecule in which a single modification of the molecule confers chirality. Studies on diol dehydratase, which is known to have a mechanism very similar to glycerol dehydratase (Poznanskaja, A. et al., Archives of Biochemistry and Biophysics, 194(2), 379-386. (1979); Yamanishi, M., et al., European journal of biochemistry, 269(18), 4484-4494. (2002)), have revealed that there are two binding modes of glycerol, pro-R and pro-S forms, depending on the position of the abstracted hydrogen, and when the substrate is bound in the pro-R form, the dehydration reaction is more dominant, whereas when it is bound in the pro-S form, the inactivation reaction is more dominant (Doitomi, K., et al., Bulletin of the Chemical Society of Japan, 87(9), 950-959. (2014)). The C3-OH group of the pro-S form faces Serine 301 of the α subunit, and the hydrogen bond between them has been reported to increase the activation energy for the movement of the C2-OH group (Bilic, L., et al., The Journal of Physical Chemistry B, 123(29), 6178-6187. (2019)). Consequently, the inactivation of pro-S is thought to occur before hydrogen recombination (Fig. 3).
[0006] On the other hand, glycerol dehydratase exhibits enzyme activity through the radical reaction of coenzyme B12. When oxygen binds to the cobalt atom of coenzyme B12 during the enzyme radical reaction, the recombination of cobalt to the adenosyl radical is blocked after the reaction is completed, resulting in inactivation. When cobalamin is inactivated, the adenosyl radical cannot be regenerated and is tightly bound to the active site, so it cannot be replaced by a new coenzyme, resulting in loss of enzyme activity (Figure 4). When introducing glycerol dehydratase in industrial applications, a study on an enzyme mutant that is resistant to inactivation has been reported (Toraya, T., Cellular and Molecular Life Sciences CMLS, 57, 106-127. (2000)).
[0007] Glycerol dehydratase, inactivated by glycerol or oxygen, can be reactivated by glycerol dehydratase reactivase. Glycerol dehydratase reactivase releases the inactive coenzyme B12 present in the inactivated enzyme and allows new coenzyme B12 to bind to the active site, restoring enzyme activity. The β subunit of glycerol dehydratase and the β subunit of glycerol dehydratase reactivase have structural similarities, and it has been hypothesized that the β subunit of reactivase replaces the β subunit of glycerol dehydratase, releasing inactive coenzyme B12 between the α and β subunits (Fig. 5) (Liao, DI, et al., Structure, 11(1), 109-119. (2003); Shibata, N., et al., Structure, 13(12), 1745-1754. (2005); Tobimatsu, T., et al., Archives of microbiology, 174, 81-88. (2000)).
[0008] To address this enzyme inactivation issue, research has been conducted from various perspectives. To improve the enzyme, attempts have been made to introduce amino acid mutations into the active site of the enzyme whose structure has been elucidated (Yamanishi, M., et al., The FEBS journal, 279(5), 793-804. (2012)). This study identified the presence of Ser301 and Gln335, which play a crucial role in distinguishing between the pro-S and pro-R forms, and when each was substituted with alanine, the inactivation rate of glycerol was lower than that of the wild type. However, in this case, the enzyme activity was also reported to decrease. Alternatively, there was an attempt to mutate the amino acids Thr172 and Ser224, which are involved in hydrogen bond formation after radical formation of the adenosyl group (Shibata, N., et al., Angewandte Chemie, 130(26), 7956-7961. (2018)), which also resulted in a lower glycerol fluorination rate than the wild type, but at the same time a decrease in enzyme activity.
[0009] On the other hand, studies focusing on the linkage of glycerol dehydratase α and β subunits have been reported. Glycerol dehydratase (KpGDHt) from K. pneumoniae has a heterotrimer dimer ((αβγ)2) form, which is composed of two α subunits that meet each other. The β and γ subunits each interact with the α subunit. Each αβγ-heterotrimer contains a coenzyme B12 molecule between the α and β subunits (Liao, DI, et al., Journal of inorganic biochemistry, 93(1-2), 84-91. (2003); Yamanishi, M., et al., European journal of biochemistry, 269(18), 4484-4494. (2002)).
[0010] Previously, there was a problem due to the dissociation of the β subunit during the purification process of glycerol dehydrogenase, and to overcome this, research was conducted to connect the α and β subunits (Wang, XD, et al., Biotechnol Lett, 31(5), 711-717. (2009)). In this study, the α and β subunits of KpGDHt were connected using a (Gly4Ser)4 linker consisting of 20 amino acids, and the mutant generated in this way exhibited a catalytic activity (kcat / Km) similar to that of the wild type. In another study, a G(PT)4T(PT)7G linker was adopted from endoglucanase A of Cellulomanas fimi, and the mutant unexpectedly had a 20°C increase in its optimum temperature for activity toward 1,2-propanediol (Maddock, DJ, et al., Biotechnol J, 12(12). (2017)).
[0011] In another study, an attempt was made to engineer KpGDHt to improve its resistance to inactivation by changing the stop codon (TAA) at the end of the α subunit to glutamine (CAA), resulting in a mutant with linked α and β subunits (Fig. 6) (Gibson et al. US Patent No. 8,569,469. (2013)). This mutant exhibited a slower inactivation rate than the wild-type enzyme in assays using cell lysates.
[0012] Under these backgrounds, the inventors of the present invention have made extensive efforts to develop a glycerol dehydratase having improved activity toward glycerol and / or resistance to oxygen, and as a result, have developed a glycerol dehydratase variant having improved both of the above characteristics and exhibiting high activity even under conditions containing a low concentration of coenzyme B12, thereby completing the present invention.
[0013] The above information described in this background section is solely intended to enhance understanding of the background of the present invention and may not include information that constitutes prior art already known to a person of ordinary skill in the art to which the present invention pertains.
[0014]
[0015] [Prior Art Literature]
[0016] [Non-patent literature]
[0017] (Non-patent literature 1) Drozdzynska A, et al., BioTechnologia, 92-100 (2011)
[0018] (Non-patent document 2) Valdehuesa, et al., Applied microbiology and biotechnology, 97, 3309-3321. (2013)
[0019] (Non-patent literature 3) Mitrea L, et al., Microbial Cell Factories, 16, 1-17. (2017)
[0020] (Non-patent Document 4) Toraya T, et al., Archives of Biochemistry and Biophysics, 203(1), 174-180. (1980)
[0021] (Non-patent literature 5) Mancia, et al., Structure, 4(3), 339-350. (1996)
[0022] (Non-patent literature 6) Shibata N, et al., Structure, 7(8), 997-1008. (1999)
[0023] (Non-patent literature 7) Kamachi T, et al., Chemistry-A European Journal, 13(28), 7864-7873. (2007)
[0024] (Non-patent document 8) Poznanskaja A, et al., Archives of Biochemistry and Biophysics, 194(2), 379-386. (1979)
[0025] (Non-patent literature 9) Yamanishi M, et al., European journal of biochemistry, 269(18), 4484-4494. (2002)
[0026] (Non-patent Document 10) Doitomi K, et al., Bulletin of the Chemical Society of Japan, 87(9), 950-959. (2014)
[0027] (Non-patent Document 11) Bilic L, et al., The Journal of Physical Chemistry B, 123(29), 6178-6187. (2019)
[0028] (Non-patent Document 12) Toraya T, Cellular and Molecular Life Sciences CMLS, 57, 106-127. (2000)
[0029] (Non-patent literature 13) Liao DI, et al., Structure, 11(1), 109-119. (2003)
[0030] (Non-patent literature 14) Shibata N, et al., Structure, 13(12), 1745-1754. (2005)
[0031] (Non-patent literature 15) Tobimatsu T, et al., Archives of microbiology, 174, 81-88. (2000)
[0032] (Non-patent literature 16) Yamanishi M, et al., The FEBS journal, 279(5), 793-804. (2012)
[0033] (Non-patent literature 17) Shibata N, et al., Angewandte Chemie, 130(26), 7956-7961. (2018)
[0034] (Non-patent literature 19) Liao DI, et al., Journal of inorganic biochemistry, 93(1-2), 84-91. (2003)
[0035] (Non-patent literature 20) Wang XD, et al., Biotechnol Lett, 31(5), 711-717. (2009)
[0036] (Non-patent literature 21) Maddock DJ, et al., Biotechnol J, 12(12). (2017)
[0037] [Patent Document]
[0038] (Patent Document 1) Gibson, et al., US Patent No. 8,569,469. (2013)
[0039]
[0040] Summary of the invention
[0041] The purpose of the present invention is to provide a fusion glycerol dehydratase variant having improved oxygen resistance and activity toward glycerol, thereby exhibiting excellent activity even under conditions of low concentrations of coenzyme B12.
[0042] Another object of the present invention is to provide a nucleic acid encoding the fused glycerol dehydratase variant, a recombinant vector comprising the nucleic acid, a recombinant microorganism transformed with the nucleic acid or the recombinant vector, and a method for producing 3-hydroxypropionic acid or 1,3-propanediol using the recombinant microorganism.
[0043]
[0044] To achieve the above object, the present invention provides a variant of a recombinant glycerol dehydratase (GDHt) in which the alpha-subunit and the beta-subunit of glycerol dehydratase are fused, the variant comprising a substitution of at least one amino acid residue selected from the group consisting of:
[0045] G19, L29, A177, A207, Y271 and V455 of the alpha subunit represented by SEQ ID NO: 1; and L113, S149 and M158 of the beta subunit represented by SEQ ID NO: 2.
[0046] The present invention also provides a nucleic acid encoding the fused glycerol dehydratase variant and a recombinant vector comprising the nucleic acid.
[0047] The present invention also provides a recombinant microorganism transformed with the nucleic acid or recombinant vector.
[0048] The present invention also provides a method for producing 3-hydroxypropionic acid, comprising the steps of culturing the recombinant microorganism in a medium containing glycerol to produce 3-hydroxypropionic acid; and obtaining the produced 3-hydroxypropionic acid.
[0049] The present invention also provides a method for producing 1,3-propanediol, comprising the steps of culturing the recombinant microorganism in a medium containing glycerol to produce 1,3-propanediol; and obtaining the produced 1,3-propanediol.
[0050]
[0051] Figure 1 is a diagram showing the production of 3-HPA from glycerol by glycerol dehydratase and the pathway for producing 3-HP and 1,3-PDO from the 3-HPA.
[0052] Figure 2 is a schematic diagram showing the reaction mechanism of glycerol dehydratase.
[0053] Figure 3 is a diagram showing two pathways and the stereostructure of the reaction according to the position of hydrogen extracted in the reaction by diol dehydratase similar to glycerol dehydratase.
[0054] Figure 4 is a schematic diagram showing the inactivation and reactivation of glycerol dehydratase by oxygen.
[0055] Figure 5 shows the mechanism by which the reactivation reaction of glycerol dehydratase occurs.
[0056] Figure 6 is a schematic diagram showing the structure of a mutant (fGDHt) in which the stop codon (TAA) at the end of the α subunit of glycerol dehydratase (KpGDHt) derived from Klebsiella pneumoniae is changed to a codon for glutamine (CAA), thereby linking the α subunit and the β subunit.
[0057] Figure 7 shows the results of purification of a mutant enzyme in which the α subunit and the β subunit are linked, and the oxygen resistance and glycerol activity of the purified mutant.
[0058] Figure 8 shows the results of a comparative analysis using the structure of WT kpGDHt with separated α and β subunits in an energy-stabilized state confirmed through molecular dynamics simulation and fGDHt with connected α and β subunits, using protein structure network analysis.
[0059] Figure 9 is a schematic diagram illustrating the process for selecting candidate mutants in the present invention. Excluding residues common to other species, the candidates were selected by analyzing the energy stability of all mutants using Rosetta Design (http: / rosettadesign.med.unc.edu / ).
[0060] Figure 10 is a graph showing the results of measuring the activity of wild-type and mutant enzymes using the 3-methyl-2-benzothiazolinone hydrazone (MBTH) method.
[0061] Figure 11 is a graph showing the resistance to oxygen by measuring the activity of wild-type and mutant enzymes using MBTH after exposing them to oxygen for 5 minutes.
[0062] Figure 12 is a graph showing the relative activity of wild-type GDHt, fGDHt, and mutants of the present invention according to exposure time to oxygen.
[0063] Figure 13 is a graph showing the productivity of recombinant microorganisms containing nucleic acids encoding wild-type GDHt, fGDHt, and variants of the present invention by culturing them under conditions of various concentrations of coenzyme B12 to confirm their ability to produce 3-HP.
[0064]
[0065] Detailed description of the invention and preferred embodiments
[0066] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.
[0067] The present inventors analyzed the three-dimensional structure of a previously reported fused glycerol dehydratase having a fused alpha-subunit and beta-subunit structure, and confirmed the energy stability of amino acids, excluding amino acids that directly interact with coenzymes, among amino acid residues present at the alpha-subunit or beta-subunit interface, and searched for a glycerol dehydratase variant with improved enzyme activity, excellent resistance to oxygen, and excellent production of 3-hydroxypropionic acid under low coenzyme B12 conditions through further research.
[0068] Based on this, the present invention provides a glycerol dehydratase variant comprising one or more amino acid changes.
[0069] The present invention provides a variant of a fusion glycerol dehydratase enzyme that is resistant to enzyme inactivation by substrates such as glycerol or oxygen. The variant comprises a modification of an amino acid residue at the interface between the alpha and beta subunits that plays a key role in the activity and / or reactivation of the glycerol dehydratase enzyme.
[0070] The present invention provides a series of processes for predicting protein structure using an in silico method to provide the above mutant, visualizing protein-protein binding, predicting protein-protein binding, and visualizing a three-dimensional binding structure.
[0071] Based on this, the present invention, from one aspect, is a mutant of a recombinant glycerol dehydratase (GDHt) in which the alpha-subunit and the beta-subunit of glycerol dehydratase are fused,
[0072] It relates to a variant comprising a substitution of any one or more amino acid residues selected from the group consisting of:
[0073] G19, L29, A177, A207, Y271 and V455 of the alpha subunit represented by sequence number 1; and
[0074] L113, S149 and M158 of the beta-subunit represented by sequence number 2.
[0075] Glycerol dehydratase belongs to the class of hydrolases that cleave carbon-oxygen bonds, and the term "glycerol hydrolase" can be used interchangeably with the term "glycerol hydrolase." Glycerol dehydratase has a quaternary structure containing two each of three types of subunits: alpha-subunit, beta-subunit, and gamma-subunit (see Figure 6). Glycerol dehydratase catalyzes the following reaction using cobalamin (B12) as a coenzyme.
[0076]
[0077] "Glycerol dehydratase", "GDHt", "glycerol dehydratase", "wild-type GDHt" or "wt GDHt" refers to wild-type GDHt of Klebsiella pneumoniae, unless otherwise stated. The term includes unprocessed GDHt and any form of GDHt obtained from processing in cells.
[0078] In one embodiment, the alpha-subunit of the wild-type glycerol dehydratase comprises an amino acid sequence represented by SEQ ID NO: 1. The beta-subunit of the wild-type glycerol dehydratase comprises an amino acid sequence represented by SEQ ID NO: 2. The gamma-subunit of the wild-type glycerol dehydratase comprises an amino acid sequence represented by SEQ ID NO: 3.
[0079] In one embodiment, the invention provides a variant comprising an additional mutation in a recombinant glycerol dehydratase having an alpha-subunit and a beta-subunit fused thereto.
[0080] In one embodiment, the recombinant glycerol dehydratase comprises a gamma-subunit having the same sequence as the gamma-subunit of wild-type glycerol dehydratase, and an alpha,beta-fused subunit in which an alpha-subunit and a beta-subunit having the same sequence as the wild-type glycerol dehydratase are linked.
[0081] Specifically, the variant may comprise a substitution for one or more residues selected from the group consisting of G19, L29, A177, A207, Y271, and V455 in the sequence of SEQ ID NO: 1.
[0082] The above variant may comprise any one or more substitutions selected from the group consisting of A207W(α), A177M(α), G19A(α), L29F(α), Y271W(α) and V455W(α).
[0083] Specifically, the variant may comprise a substitution for one or more residues selected from the group consisting of L113, S149 and M158 in the sequence of SEQ ID NO: 2.
[0084] The above variant may comprise one or more substitutions selected from the group consisting of L113Y(β), L113F(β), S149I(β), L113W(β), S149M(β), M158W(β) and M158Y(β).
[0085] The above variant may comprise any one substitution selected from the group consisting of:
[0086] A177M(α), L113W(β) and M158W(β);
[0087] A177M(α) and L113W(β); and
[0088] A177M(α) and M158W(β).
[0089] In a specific embodiment, the variant may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 12.
[0090] "Glycerol dehydratase mutant", "vt GDHt" or "mutant GDHt" encompasses any of the various forms of mutant forms of the GDHt molecule, including forms in which GDHt is linked to another molecule, such as by fusion or chemical conjugation, characterized by having one or more amino acid mutations that affect the interaction of glycerol dehydratase with coenzyme B12 and / or the glycerol substrate. The mutations may include substitutions, deletions, truncations or alterations of the wild-type amino acid residues normally located at that position. Mutants obtained by amino acid substitutions are preferred. Unless otherwise stated, a glycerol dehydratase mutant may be referred to herein as a GDHt mutant peptide sequence, a GDHt mutant polypeptide, a GDHt mutant protein or a GDHt mutant.
[0091] When referring to amino acid positions of the GDHt protein and sequence fragments thereof, the alpha-subunit, the beta-subunit of GDHt or the alpha, beta-fusion subunit of recombinant GDHt in the present invention, it is determined by reference to the amino acid sequences of the alpha-subunit, the beta-subunit and the alpha, beta-fusion subunit of wild-type GDHt as set forth in SEQ ID NOs: 1, 2 and 4. For example, the corresponding amino acid position in another GDHt alpha-subunit can be identified by amino acid sequence alignment with SEQ ID NO: 1, the corresponding amino acid position in another GDHt beta-subunit can be identified by amino acid sequence alignment with SEQ ID NO: 2, and the corresponding amino acid position in another GDHt alpha, beta-fusion subunit can be identified by amino acid sequence alignment with SEQ ID NO: 4. Accordingly, unless otherwise stated herein, amino acid positions in glycerol dehydratase and its alpha-subunit, beta-subunit, and alpha, beta-subunit are amino acid positions numbered according to SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 4, respectively. In this case, a specific residue may be referred to as [amino acid residue / position], and considering that the GDHt of the present invention has a quaternary structure including three types of subunits, it may be referred to as [amino acid residue / position / (subunit)]. The amino acid residues may be expressed by three-letter abbreviations and one-letter abbreviations. For example, when "Ala177(α)", "A177(α)" are mentioned, this refers to the alanine residue A at position 177 of the alpha-subunit of SEQ ID NO: 1, or the amino acid residue at the corresponding position in the polypeptide sequence of the alpha-subunit of another GDHt by alignment. To perform sequence alignments to determine amino acid positions, you can use the Basic Local Alignment Search Tool available at https: / blast.ncbi.nlm.nih.gov / Blast.cgi with default parameters.
[0092] The designations for various forms of GDHt variants may be used herein to refer to the same mutation. When referring to GDHt variant proteins herein, a single amino acid substitution is described as [original amino acid residue / position / substituted amino acid residue]. Additionally, since the GDHt of the present invention has a quaternary structure comprising three subunits, the subunits are described as [original amino acid residue / position / substituted amino acid residue / (subunit)] to specify them. For example, a mutation from alanine to methionine at position 177 may be referred to as A42, Ala42, Ala42, A177M, or Ala42Met. For example, a mutation from alanine to methionine at position 177 of the alpha subunit represented by SEQ ID NO: 1 may be referred to as A42(α), Ala42(α), Ala 42(α), A177M(α), or Ala42Met(α). Single amino acid substitutions may be linked together using a comma (,") to represent combinatorial variants at multiple given positions.
[0093] As used herein, "mutation" refers to a modification of a protein, including the replacement of an amino acid with an amino acid having similar biochemical properties without causing a loss of the protein's structure, biological, or biochemical function. An "amino acid substitution" is a substitution that maintains the amino acid's structure but replaces it with an amino acid having a side chain with different chemical properties. Naturally occurring amino acids can be categorized into amino acids with side chains exhibiting similar properties, and this is well known. These categories include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). The present invention provides a GDHt variant constructed through an amino acid substitution strategy based on Klebsiella pneumoniae GDHt, and shows that it can still retain activity.
[0094] The GDHt variant of the present invention may include not only the sequence of the GDHt variant described herein, but also biological equivalents thereof, as long as the desired function is maintained. For example, additional changes may be made to the amino acid sequence of the protein to further improve the physical properties or other biological characteristics of GDHt. Such modifications include, for example, deletions, insertions, and / or substitutions of amino acid sequence residues of the protein. That is, as previously described, these modifications are made based on the relative similarity of the amino acid residue substitutions, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid residue substitutions reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine have similar sizes; and phenylalanine, tryptophan, and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine, and histidine; alanine, glycine, and serine; And phenylalanine, tryptophan, and tyrosine are biologically functional equivalents.
[0095] The GDHt variant of the present invention is interpreted to also include a sequence that shows substantial identity with the sequence described in the sequence number. The substantial identity means a sequence that shows at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the Internet. BLAST is accessible at www.ncbi.nlm.nih.gov / BLAST / . How to compare sequence homology using this program can be found at www.ncbi.nlm.nih.gov / BLAST / blast_ help.html.
[0096] Based on this, each subunit of the GDHt variant of the present invention may have 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homology with the specified SEQ ID NOs: 1 to 4 described in the specification. Such homology can be determined by sequence comparison and / or alignment using methods known in the art. For example, the percent sequence homology of the nucleic acid or protein of the present invention can be determined using a sequence comparison algorithm (i.e., BLAST or BLAST 2.0), manual alignment, or visual inspection.
[0097]
[0098] In particular, the present inventors searched for a mutant that maximizes the enzyme properties by adding additional mutations to a previously reported recombinant glycerol dehydratase in which alpha- and beta-subunits are linked. By using a recombinant glycerol dehydratase in which alpha- and beta-subunits are linked, it is expected that the degradation of the beta-subunit will be reduced, thereby improving the resistance to GDHt inactivation. In addition, the above properties can be maximized through amino acid substitutions present at the interface of the alpha- and beta-subunits.
[0099] In one embodiment, for the recombinant glycerol dehydratase, a mutant of GDHt can be designed through amino acid mutation of wild-type GDHt and expressed in the form of a fusion protein variant.
[0100] In a specific embodiment, the alpha-subunit and beta-subunit fused glycerol dehydratase variant can be prepared with reference to the literatures Wang XD, et al., Biotechnol Lett, 31(5), 711-717. (2009); Maddock DJ, et al., Biotechnol J, 12(12). (2017); Gibson, et al., US Patent No. 8,569,469. (2013). In one particular embodiment, a recombinant GDHt in the form of an alpha-subunit and a beta-subunit fused can be prepared by changing the last stop codon (TAA) of the alpha-subunit to glutamine (CAA). Additionally, one skilled in the art will be able to produce recombinant glycerol dehydratase variants comprising linked alpha-subunits and beta-subunits by utilizing methods known in the art for linking two different proteins.
[0101] As used herein, "fusion" refers to the integration of two molecules with different or identical functions or structures. For example, fusion may be achieved by any physical, chemical, or biological method that allows the beta subunit of glycerol dehydratase to bind to the alpha subunit of glycerol dehydratase. The fusion may preferably be achieved by a linker peptide, which can mediate the fusion of the bioactive molecule with various positions of the alpha subunit and beta subunit of the glycerol dehydratase of the present invention.
[0102] Specifically, the alpha-subunit and the beta-subunit are characterized in that they are connected via a linker.
[0103] The alpha subunit of the above glycerol dehydratase variant may be connected to the beta subunit by a linker. The linker may be a peptide linker and may have a length of about 10-25 aa. For example, the linker may include, but is not limited to, hydrophilic amino acids such as glycine and / or serine.
[0104] Specifically, the linker may be any one selected from the group consisting of, but is not limited to:
[0105] (G4S) a , G(PT) b T(PT) c G and QGGIPV,
[0106] (wherein a is an integer from 1 to 8, and b and c are integers from 2 to 10).
[0107] Specifically, the linker is characterized by being positioned between the C-terminus of the alpha-subunit and the N-terminus of the beta-subunit, but is not limited thereto, and is included in the scope of the present invention as long as it is expected to solve the problem of enzyme inactivation through the binding of the alpha-subunit and the beta-subunit.
[0108] By designing a mutant that increases the oxygen resistance of GDHt and structural stability through amino acid mutation of wild-type GDHt, and linking its alpha-subunit and beta-subunit to express it in the form of a recombinant glycerol dehydratase mutant, the expression amount of the fusion protein increases, and the biological properties are improved to resolve the decrease in enzyme activity due to the decomposition of the beta-subunit.
[0109] From another perspective, the present invention relates to a nucleic acid encoding the fused glycerol dehydratase variant. The nucleic acid encoding the fused glycerol dehydratase variant of the present invention can be isolated to recombinantly produce the fused glycerol dehydratase variant. Those skilled in the art will be able to recombinantly produce the alpha, beta-fused subunits, and gamma-fused subunits of glycerol dehydratase separately or from a single nucleic acid, based on the teachings herein.
[0110] The term "nucleic acid" encompasses DNA (gDNA and cDNA) and RNA molecules. Nucleotides, the basic structural units of nucleic acids, include not only natural nucleotides but also analogues with modified sugar or base moieties. The sequence of a nucleic acid encoding a glycerol dehydratase variant of the present invention may be modified. Such modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides.
[0111] In a specific embodiment, the nucleic acid encoding the variant may comprise a base sequence selected from the group consisting of SEQ ID NOs: 17 to 24.
[0112] DNA encoding the above glycerol dehydratase variants (subunits and fusion subunits) can be readily isolated or synthesized using conventional molecular biological techniques (for example, by using oligonucleotide probes that can specifically bind to CH3A(EW) and CH3B(RVT) DNA), and the nucleic acid is isolated and inserted into a replicable vector for further cloning (amplification of DNA) or further expression. Based on this, the present invention relates to a recombinant expression vector comprising the above nucleic acid from another aspect.
[0113] As used herein, the terms "expression vector" and "vector" refer to a means for expressing a target gene in a host cell, and include viral vectors such as plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors. Components of a vector typically include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more antibiotic resistance marker genes, an enhancer element, a promoter, and a transcription termination sequence. A nucleic acid encoding a glycerol dehydratase variant is operably linked to the promoter and the transcription termination sequence, etc.
[0114] "Operably linked" means a functional association between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, whereby the regulatory sequence regulates transcription and / or translation of the other nucleic acid sequence.
[0115] In the case of a prokaryotic cell as a host, it is common to include a strong promoter that can drive transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter), a ribosome binding site for translation initiation, and a transcription / translation termination sequence. In addition, for example, when a eukaryotic cell is used as a host, promoters derived from the genome of mammalian cells (e.g., metallothionine promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, and Rous sarcoma virus (RSV) promoter) can be used, and generally have a polyadenylation sequence as a transcription termination sequence.
[0116] In another aspect, the present invention relates to a recombinant microorganism transformed with the recombinant expression vector. The recombinant microorganism used to produce the variant of the present invention may be a prokaryotic cell, yeast cell, or higher eukaryotic cell, but is not limited thereto.
[0117] Prokaryotic host cells can be used, such as strains of the genus Bacillus, such as Escherichia coli, Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis and Staphylococcus (e.g., Staphylococcus carnosus).
[0118] However, animal cells are of greatest interest, and examples of useful host cell lines include, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080.
[0119] There is an industrial demand for a method for producing 3-hydroxypropionic acid from glycerol, the reaction of which is illustrated in Figure 1. To produce 3-hydroxypropionic acid, the recombinant microorganism must express the glycerol dehydratase enzyme aldehyde dehydrogenase.
[0120] In one embodiment, a recombinant microorganism can be utilized in which the glycerol dehydratase variant of the present invention is introduced into a host cell endogenously expressing aldehyde dehydrogenase. Host cells endogenously expressing aldehyde dehydrogenase include E. coli, Halobacterium volcanii, Acinetobacter baylyi, Saccharolobus solfataricus, Azospirillum brasilense, and the like.
[0121] In another embodiment, even when using a host cell that does not endogenously express aldehyde dehydrogenase, a nucleic acid encoding aldehyde dehydrogenase can be introduced into the host cell to express aldehyde dehydrogenase. Examples of the nucleic acid encoding aldehyde dehydrogenase include aldh, ALDH1, araE, LhpG, proA, puuC, ALDH3A2, ALDH3A1, ALDH1A1, etc.
[0122] In another embodiment, even when using a host cell that endogenously expresses aldehyde dehydrogenase, a nucleic acid encoding aldehyde dehydrogenase can be introduced into the host cell to increase the expression of aldehyde dehydrogenase.
[0123] In one embodiment of the present invention, a recombinant E. coli strain into which a vector expressing a glycerol dehydratase variant of the present invention and a vector expressing alpha-ketoglutaric semialdehyde dehydrogenase (KGSADH) derived from Azospirillum brasilense as an aldehyde dehydrogenase were introduced was used as a parent strain; however, any strain expressing an aldehyde dehydrogenase can be used without limitation, and this also includes a strain expressing an aldehyde dehydrogenase introduced from outside.
[0124] The term 'aldehyde dehydrogenase' of the present invention refers to an enzyme that catalyzes a reaction that oxidizes 3-hydroxypropionaldehyde to produce 3-hydroxypropionic acid.
[0125] The above aldehyde dehydrogenase may be 3-hydroxypropionaldehyde dehydrogenase, succinic semialdehyde dehydrogenase, gamma-glutamyl-gamma-aminobutyraldehyde dehydrogenase, preferably alpha-ketoglutaric semialdehyde dehydrogenase (KGSADH).
[0126] Based on this, the recombinant microorganism can additionally express aldehyde dehydrogenase. The recombinant microorganism can be a microorganism for producing 3-hydroxypropionic acid.
[0127] There is an industrial demand for a method for producing 1,3-propanediol from glycerol, the reaction of which is illustrated in Figure 1. In order to produce 1,3-propanediol through the reaction, the recombinant microorganism must express 1,3-propandiol oxidoreductase (PDOR).
[0128] In one embodiment, a recombinant microorganism can be utilized in which the glycerol dehydratase variant of the present invention is introduced into a host cell endogenously expressing 1,3-propanedioloxidoreductase. Examples of the host cell endogenously expressing 1,3-propanedioloxidoreductase include Clostridium butyricum, Clostridium pasteurianum, preferably Escherichia coli, Pseudomonas putida, Klebsiella pneumoniae, Citrobacter freundii, and the like.
[0129] In another embodiment, even when using a host cell that does not endogenously express 1,3-propanediol oxidoreductase, a nucleic acid encoding 1,3-propanediol oxidoreductase can be introduced into the host cell to cause it to express the same. Examples of nucleic acids encoding 1,3-propanediol oxidoreductase include pddh, adhE, dhaT, gldA, and kduD.
[0130] In another embodiment, even when using a host cell that endogenously expresses 1,3-propanedioloxidoreductase, a nucleic acid encoding aldehyde dehydrogenase can be introduced into the host cell to increase the expression of aldehyde dehydrogenase.
[0131] Any strain expressing 1,3-propanediol oxidoreductase can be used without limitation for the production of 1,3-propanediol, including strains expressing 1,3-propanediol oxidoreductase introduced from outside.
[0132] Based on this, the recombinant microorganism can additionally express 1,3-propanediol oxidoreductase. The recombinant microorganism can be a microorganism for producing 1,3-propanediol.
[0133] The term '1,3-propanediol oxidoreductase' of the present invention refers to an enzyme that catalyzes a reaction that reduces 3-hydroxypropionaldehyde to produce 1,3-propanediol.
[0134] In addition, in order to increase the production yield of 3-hydroxypropionic acid or 1,3-propanediol by maintaining the enzymatic activity of glycerol dehydratase, it is preferable that the recombinant microorganism express glycerol dehydratase reactivase (GDHt reactivase).
[0135] In one embodiment, a recombinant microorganism can be utilized in which the glycerol dehydratase variant of the present invention is introduced into a host cell endogenously expressing glycerol dehydratase reactivator. Examples of the host cell endogenously expressing glycerol dehydratase reactivator include Clostridium pasteurianum, preferably Klebsiella pneumoniae, Salmonella Typhimurium, Klebsiella Michiganesis, Citrobacter freundii, etc.
[0136] In another embodiment, even when using a host cell that does not endogenously express glycerol dehydratase reactivase, a nucleic acid encoding glycerol dehydratase reactivase can be introduced into the host cell to cause it to express the same. Examples of nucleic acids encoding glycerol dehydratase reactivase include pduG, pduH, gdrA, gdrB, ddrA, ddrB, dhaF, etc.
[0137]
[0138] The glycerol dehydratase variant according to the present invention is a variant having improved resistance to inactivation of the enzyme by oxygen or inactivation of coenzyme B12, and exhibited a high yield even in a medium containing a low coenzyme B12 level of 0.4 μM or less when producing 3-hydroxypropionic acid using a microorganism.
[0139] From another perspective, the present invention relates to a method for producing 3-hydroxypropionic acid, comprising the steps of culturing the recombinant microorganism in a medium containing glycerol to produce 3-hydroxypropionic acid; and recovering the produced 3-hydroxypropionic acid.
[0140] The above manufacturing method may further include a step of producing 3-hydroxypropionaldehyde (3-HPA) from glycerol through the activity of glycerol dehydratase; and a step of producing 3-hydroxypropionic acid (3-HP) from 3-hydroxypropionaldehyde (3-HPA) through the activity of aldehyde dehydrogenase.
[0141] In the above production method, the recombinant microorganism can be cultured in the presence of glycerol at a temperature of about 20-45°C, and can be cultured using, alone or in combination, (i) carbohydrates containing monosaccharides, such as glucose, sucrose, lactose, fructose, maltose, molasses, starch or cellulose, (ii) oils and fats, such as soybean oil, sunflower oil, peanut oil or coconut fat, (iii) fatty acids, such as palmitic acid, stearic acid or linoleic acid, (iv) alcohols, such as glycerol or methanol, (v) amino acids, such as L-glutamate or L-valine, (vi) organic acids, such as acetic acid, etc., according to a known method. In some cases, a known nitrogen source, phosphorus source, metal salts required for growth, precursors or pH regulators may be included.
[0142] The cultured and expressed 3-hydroxypropionic acid can be separated and recovered, and the culture solution can be passed through a filter, or the culture solution and the expressed 3-hydroxypropionic acid can be separated using a centrifuge or sedimentation device, and pure 3-hydroxypropionic acid can be recovered using an additional osmosis or purification method.
[0143]
[0144] The glycerol dehydratase variant according to the present invention is a variant with improved resistance to inactivation of the enzyme by oxygen or inactivation of coenzyme B12, and a high yield is expected when producing 1,3-propanediol using a microorganism.
[0145] A method for producing 1,3-propanediol using microorganisms is described in (RK Saxena, et al., Biotechnology Advances, Volume 27, Issue 6, 895-913, (2009)), etc., and a person skilled in the art will be able to produce 1,3-propanediol in high yield by referring to the description in this specification and the above-mentioned documents.
[0146] Accordingly, from another perspective, the present invention relates to a method for producing 1,3-propanediol, comprising the steps of culturing the recombinant microorganism in a medium containing glycerol to produce 1,3-propanediol; and recovering the produced 3-hydroxypropionic acid.
[0147] The above manufacturing method may further include a step of producing 3-hydroxypropionaldehyde (3-HPA) from glycerol through the activity of glycerol dehydratase; and a step of producing 1,3-propanediol (1,3-PDO) from 3-hydroxypropionaldehyde (3-HPA) through the activity of 1,3-propanediol oxidoreductase.
[0148] As for the culture conditions of microorganisms or the method for isolating and recovering the product, the contents of the method for producing 3-hydroxypropionic acid described above can be equally applied.
[0149]
[0150] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0151]
[0152] Example 1: Preparation and characterization of fused glycerol dehydratase (fGDHt).
[0153] Example 1-1. Preparation of fGDHt
[0154] The glycerol dehydratase variant of the present invention with improved oxygen resistance or activity toward glycerol can be prepared based on glycerol dehydratase (KpGDHt) derived from Klebsiella pneumoniae, which exists in nature. In the present invention, the variant was developed according to the following sequence: changes in enzyme properties (resistance to oxygen inactivation, activity toward substrate) according to the linkage of glycerol dehydratase α and β subunits; selection of variant candidates with improved enzyme stability toward oxygen based on sequence and computer analysis; and analysis of enzyme properties of the variant candidates.
[0155] Based on previously reported information (Gibson et al. US Patent No. 8,569,469. (2013)), a fusion glycerol dehydratase having a structure in which an α subunit and a β subunit are linked was prepared and purified (Fig. 6, a form in which the stop codon (TAA) at the end of the α subunit is changed to glutamine (CAA)).
[0156] The amino acid sequence and base sequence of each subunit fused with the above GDHt are shown in Table 1 and Table 2, respectively.
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163] Example 1-2. Characterization of manufactured fGDHt
[0164] Analysis of the purified enzyme revealed that adding a peptide linker between the α and β subunits of kpGDHt increased the enzyme's resistance to oxygen inactivation by approximately 37% based on half-life. Furthermore, its activity toward the substrate glycerol increased approximately fivefold (Fig. 7).
[0165] A computer-based structural analysis was performed to determine how the connection of α-β subunits affects the enzyme properties. The wild-type Klebsiella pneumoniae glycerol dehydratase (WT kpGDHt), whose structure has been elucidated, and a fusion GDHt (fGDHt) made using it as a template were constructed. The structures of the original WT kpGDHt, in which the α and β subunits are separated in an energy-stabilized state confirmed through molecular dynamics simulation, and the structures of fGDHt, in which the α and β subunits are connected, were compared and analyzed through Protein Structure Networks Analysis. As a result, the number of interactions between amino acid residues on the surface between the α and β subunits was confirmed to be increased in fGDHt compared to WT kpGDHt (Fig. 8). This suggests that the interaction between the α subunit and the β subunit affects the stability of the enzyme and is responsible for the changes in enzyme properties.
[0166]
[0167] Example 2: Selection of candidate variants based on sequence and computational analysis.
[0168] To further enhance the stability of the enzyme through amino acid mutations at the interface between the α and β subunits, GDHt sequence analysis and computational energy stabilization analysis were performed. First, amino acids existing at the interface of the α and β subunits were identified. Specifically, by performing Contact Surface using Pymol software (see https: / pymolwiki.org / index.php / Contact_Surface), the solvent accessible surface area (ASA) for each subunit of GDHt when it exists independently and when it forms a quaternary structure was calculated. Then, 87 amino acids whose accessible surface area decreases by more than 1Å2 when forming a quaternary structure were selected as amino acids existing at the interface of the α and β subunits. To alter the interactions between subunits, 81 amino acid residues, excluding six amino acid residues that directly interact with coenzyme B12 or the substrate, were compared with the sequence information of other species of glycerol dehydratase obtained through BLAST and multiple sequence alignment (MSA). Among the 81 residues, residues that were confirmed to be identical when compared with glycerol dehydratase of other species were judged to be amino acid residues important for enzyme activity and were excluded, and 63 amino acid residues were finally selected (Fig. 9).
[0169] For the 63 selected amino acid residues, 19 amino acid mutants were selected, excluding the wild type at each amino acid position, and the energy stability of all mutants was analyzed through Rosetta Design (http: / rosettadesign.med.unc.edu / ). The top 19 mutant candidates predicted to have low ΔΔG biding energy were finally selected (Fig. 9). Table 3 below shows the analysis results for the 19 mutant candidates.
[0170]
[0171] Example 3: Enzyme Characterization of Candidate Mutants
[0172] Example 3-1. Activity analysis for glycerol
[0173] The activities of the wild-type and mutant enzymes were measured at 25°C using 3-methyl-2-benzothiazolinone hydrazone (MBTH). To exclude oxygen inactivation, the enzymes were incubated for 5 minutes in 35 mM phosphate buffer (pH 8.0) stirred in a negative pressure pump. The reaction was initiated by the addition of glycerol. The absorbance values measured at OD 670 nm were compared with those of the wild-type fGDHt to determine the relative substrate activity (Fig. 10). The MBTH assay was performed as follows:
[0174] First, an assay mixture was prepared by mixing glycerol dehydratase, coenzyme B12, 0.05 M potassium chloride (KCl), and 35 mM phosphate buffer (pH 8.0). The reaction was then initiated by adding glycerol as a substrate to the mixture. After the reaction was carried out for 5 minutes, the reaction was terminated by adding 12 mg / ml MBTH and 0.1 M potassium citrate buffer (pH 3.6). Five minutes after the reaction was terminated, FeCl3 was added, and the reaction was carried out for 15 minutes, and the absorbance was measured at 670 nm.
[0175] When the enzyme activity of 19 selected mutant candidates toward the substrate glycerol was measured, two mutants (M158W(β), M158Y(β)) showed higher activity toward glycerol than the wild-type fGDHt. In addition, it was confirmed that 10 mutants (L113Y(β), A207W(α), L113F(β), A177M(α), G19A(α), S149I(β), L113W(β), S149M(β), L29F(α), Y271W(α)) showed enzyme activity that was 60% or higher compared to the wild-type fGDHt. Additional experiments were performed on the above 12 mutants.
[0176]
[0177] Example 3-2. Oxygen resistance analysis
[0178] To observe inactivation by oxygen, the enzyme was reacted with coenzyme B12 for 5 minutes in 35 mM phosphate buffer (pH 8.0) without removing oxygen, and then the substrate glycerol was added and MBTH assay was performed for 5 minutes (Fig. 11). The assay was calculated as a relative activity, with the activity when the enzyme was not exposed to oxygen set to 100%. As a result, 10 mutants (L113W(β), V455W(α), G19A(α), A177M(α), A207W(α), L113Y(β), L113F(β), M158W(β), Y271W(α), S149M(β)) showing inactivation resistance higher than or similar to that of the wild-type fGDHt were selected, and an experiment was conducted to determine the half-life of the selected mutants against oxygen.
[0179] The resistance of 10 mutants to oxygen inactivation was analyzed and their half-lives were calculated. Inactivation by oxygen was induced by reaction with coenzyme B12 in 35 mM phosphate buffer (pH 8.0) without removing oxygen. Enzyme activity was measured by varying the exposure time to oxygen from 0 to 60 minutes. The relative activity over time was determined based on the activity of the enzyme not exposed to oxygen (0 minutes of exposure) as the standard (100%) (Fig. 12). Table 4 below shows the half-lives of each mutant.
[0180]
[0181] As a result, four mutants with increased resistance to oxygen inactivation compared to fGDHt were identified: (A177M(α), V455W(α), M158W(β), L113W(β)).
[0182] Additionally, the following mutants having combinations of the above amino acid substitution mutations were produced and their enzymatic activity and oxygen resistance were analyzed: A177M(α) / L113W(β), A177M(α) / M158W(β), L113W(β) / M158W(β), and A177M(α) / L113W(β) / M158W(β). Among the mutants, A177M(?) / L113W(β), A177M(α) / M158W(β), and A177M(α) / L113W(β) / M158W(β)) exhibited enzymatic activity and oxygen resistance that was 7-fold, 2.5-fold, and 10.7-fold higher, respectively, compared to fGDHt.
[0183]
[0184] Example 3-3. Measurement of enzyme reaction rates for substrates of major mutants
[0185] In Example 3-2, mutants with increased oxygen resistance compared to fGDHt, namely L113W(β), A177M(α), L113F(β), M158W(β), A177M / L113W(α / β), A177M / M158W(α / β), A177M / L113W / M158W(α / β / β), were purified, and their enzymatic reaction rates toward glycerol were measured. To measure the enzymatic reaction rates, an MBTH assay was performed for 5 minutes under conditions of 35 mM phosphate buffer (pH 8.0) from which oxygen was removed by stirring in a negative pressure pump, 2 μM coenzyme B12, and various concentrations of glycerol.
[0186] Km and Kcat were calculated using the following mathematical equation (Michaelis-Menten equation):
[0187] [Mathematical Formula 1]
[0188]
[0189] Km is the Michaelis constant, and Kcat is the enzyme turnover number.
[0190] The Km, Kcat, and Kcat / Km of each mutant are shown in Table 5 below.
[0191]
[0192] In particular, among the above mutants, L113F(β) and A177M / M158W(α / β) showed kcat / Km values, which are indicators of enzyme reaction rate, that were 6% and 8% higher than fGDHt, respectively. The remaining mutants also showed sufficiently high kcat / Km values.
[0193] The amino acid sequence and base sequence of the alpha-beta fusion subunit of each mutant used in the experiment are shown in Tables 6 and 7, respectively. The gamma subunit of the mutants is identical to that of native GDHt.
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210] Example 3-4. Production of 3-HP through flask cultivation of recombinant E. coli containing mutants
[0211] Considering the resistance to oxygen and high enzyme reaction rate, it was thought that the mutants of the present invention could sufficiently produce 3-HP even under conditions containing a small concentration of expensive coenzyme B12, and this was confirmed.
[0212] Specifically, a plasmid expressing the seven mutant genes of Example 3-4 and Glycerol dehydratase reactivase (GDHt reactivation enzyme) was constructed. The constructed plasmid was introduced into E. coli W strain together with a plasmid expressing α-ketoglutaric semialdehyde dehydrogenase (KGSADH) to create a recombinant E. coli, which was then cultured to produce 3-HP (for a specific method, see Park, YS, Choi, UJ, Nam, NH et al., Sci Rep 7, 17155 (2017).).
[0213] Recombinant cells were cultured in Modified M9 (2 g / L NaCl, 1 g / L Yeast Extract, 2 g / L NH4Cl, 0.5 g / L MgSO4ㆍ7H2O, and 100 mM potassium phosphate buffer pH 7.0) and 100 mM glycerol, and 34 μg / ml chloramphenicol and 200 μg / ml ampicillin were added to the medium to stabilize the plasmid. A single colony was first cultured in a 4 ml test tube at 37°C and 180 rpm for one day, and then 20 ml of the culture was transferred to a 100 ml flask when the OD600 value became 0.1, and the culture was cultured under the same temperature and rotation conditions until the OD600 became 1.0. 50 ml of the above culture solution was placed in a 250 ml flask and cultured, transferred when OD600 became 0.1, and cultured at 37℃, 180 rpm, in a light-blocking state until OD600 became between 0.9 and 1.0. After that, 0.1 mM IPTG and different concentrations of coenzyme B12 (2.0, 0.4, 0.08, 0.016 μM) were added to induce protein expression and cultured for 24 hours. The pH was measured at 8 and 16 hours during culture, and the pH was adjusted to 7.0 using 10 M NaOH. The culture solution was collected, centrifuged at 13,000 rpm for 10 minutes to obtain the supernatant, and the concentration of 3HP was analyzed through HPLC.
[0214] As a result of the experiment, under the condition of 0.016 μM coenzyme B12, the 3HP production was 0.95 times (L113F(β)), 1.07 times (L113W(β)), 2.33 times (M158W(β)), 2.69 times (A177M(α)), 1.47 times (A177M / L113W(α / β)), (4.07 times A177M / M158W(α / β)), (1.86 times A177M / L113W / M158W(α / β / β)) compared to fGDHt, and under the condition of 0.08 μM coenzyme B12, the 3HP production was 1.12 times (L113F(β)), 1.21 times (L113W(β)), (1.36 times M158W(β)), It showed 3HP production of 1.56 times (A177M(α)), 1.26 times (A177M / L113W(α / β)), 1.8 times (A177M / M158W(α / β)), and 1.34 times (A177M / L113W / M158W(α / β / β)).
[0215] In particular, the A177M(α) mutant and A177M / M158W (α / β) mutant showed higher 3HP production compared to fGDHt in all intervals (A177M(α): 2.69-fold 0.016 μM, 1.56-fold 0.08 μM, 1.12-fold 0.4 μM, 1.23-fold 2.0 μM; A177M / M158W(α / β): 4.07-fold 0.016 μM, 1.8-fold 0.08 μM, 1.23-fold 0.4 μM, 1.25-fold 2.0 μM).
[0216]
[0217] The fused glycerol dehydratase variant according to the present invention exhibits high activity toward glycerol while also exhibiting excellent resistance to oxygen, thereby solving the problem of oxygen-induced inactivation of coenzyme B12. Furthermore, the recombinant strain containing the variant exhibits high activity even in media containing low concentrations of coenzyme B12, thereby reducing costs associated with coenzyme B12.
[0218]
[0219] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0220]
[0221] Electronic file attached.
Claims
1. A mutant of recombinant glycerol dehydratase (GDHt) in which the alpha-subunit and beta-subunit of glycerol dehydratase are fused. A variant comprising a substitution of any one or more amino acid residues selected from the group consisting of: G19, L29, A177, A207, Y271 and V455 of the alpha subunit represented by sequence number 1; and L113, S149 and M158 of the beta-subunit represented by sequence number 2.
2. A variant according to claim 1, characterized in that the variant comprises at least one substitution selected from the group consisting of G19A(α), L29F(α), A177M(α), A207W(α), Y271W(α), and V455W(α).
3. A variant according to claim 1, characterized in that the variant comprises at least one substitution selected from the group consisting of L113Y(β), L113F(β), L113W(β), S149I(β), S149M(β), M158W(β), and M158Y(β).
4. In the first paragraph, the variant is characterized in that it comprises any one substitution selected from the group consisting of: A177M(α), L113W(β) and M158W(β); A177M(α) and L113W(β); and A177M(α) and M158W(β).
5. A variant according to claim 1, characterized in that the alpha-subunit and the beta-subunit are connected via a linker.
6. A variant according to claim 5, wherein the linker is any one selected from the group consisting of: (G4S) a , G(PT) b T(PT) c G and QGGIPV, (wherein a is an integer from 1 to 8, and b and c are integers from 2 to 10).
7. A variant according to claim 5, characterized in that the linker is located between the C-terminus of the alpha-subunit and the N-terminus of the beta-subunit.
8. A nucleic acid encoding a fused glycerol dehydratase variant according to paragraph 1.
9. A recombinant vector comprising a nucleic acid according to Article 8.
10. A recombinant microorganism transformed with a nucleic acid according to Article 8 or a recombinant vector according to Article 9.
11. A recombinant microorganism further expressing aldehyde dehydrogenase according to claim 10.
12. A recombinant microorganism further expressing 1,3-propandiol oxidoreductase according to claim 10.
13. A step of culturing a recombinant microorganism according to Article 11 in a medium containing glycerol to produce 3-hydroxypropionic acid; and A method for producing 3-hydroxypropionic acid, comprising a step of recovering the produced 3-hydroxypropionic acid.
14. A step of culturing a recombinant microorganism according to Article 12 in a medium containing glycerol to produce 1,3-propanediol; and A method for producing 1,3-propanediol, comprising a step of recovering the produced 1,3-propanediol.
15. A pharmaceutical composition for preventing or treating cancer, comprising a fusion protein comprising VEGFR1 (vascular endothelial growth factor receptor 1) domain 2, VEGFR1 domain 3, and the Fc region of an antibody as an active ingredient, and for co-administration with a PD-1 antagonist or a PD-L1 antagonist.
Citation Information
Patent Citations
Machine foe making pins
US2013A
B12-dependent dehydratases with improved reaction kinetics
US8569469B2
Recombinant microorganism having improved productivity of glycerol dehydration product and uses thereof
KR1020140032057A
Variant sucrose transporter polypeptides
KR1020140135803A
Combination of a PD-1 antagonist and a vegfr / fgfr / ret tyrosine kinase inhibitor for treating cancer
KR1020170122809A
